Brief: Acadia Pharmaceuticals Announces Health Canada Approval Of DAYBUE (Trofinetide) For The Treatment Of Rett Syndrome
16/10/2024 21:08
Oct 16 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O :
* ACADIA PHARMACEUTICALS ANNOUNCES HEALTH CANADA APPROVAL OF
DAYBUE™ (TROFINETIDE) FOR THE TREATMENT OF RETT SYNDROME
Source text for Eikon: ID:nBw9H2D5Ra
Further company coverage: ACAD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acadia Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study (updated)
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry